CrushSCI.com
102Average days
93.5Median days
40Fastest days
237Longest days
1662025 publications

Paper Review Records

All Paper Review Records

30 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

237 days

Ex vivo JAK and TNF inhibitor–modulated immune signatures guide first-line therapy selection in rheumatoid arthritis

Authors
Sagrario Corrales; Carlos Pérez-Sánchez; Tomas Cerdó; Christian Merlo; Beatriz Malvar-Fernández; Samuel García; Laura Muñoz-Barrera; Ismael Sanchez-Pareja; Lydia Formanti; Elena Moreno-Caño; Rafaela Ortega-Castro; Jerusalén Calvo; Concepción Aranda-Varela; Lourdes Ladehesa; Pilar Font; M. Carmen Abalos-Aguilera; Desirée Ruiz-Vilchez; Mª Ángeles Aguirre; Nuria Barbarroja; Marta E. Alarcon-Riquelme; Alejandro Escudero-Contreras; Chary López-PedreraShow moreShow less
Affiliations
1. IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain; 2. Department of Cell Biology, Immunology and Physiology, Agrifood Campus of International Excellence, University of Córdoba, Córdoba, Spain; 3. Cobiomic Bioscience, EBT IMIBIC/UCO, Córdoba, Spain; 4. Rheumatology and Immuno-Mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain; 5. Center for Genomics and Oncological Research (GENYO), Granada, Spain; 6. Institute for Environmental Medicine, Stockholm, SwedenShow moreShow less
Source PDF DOI Publisher page
72 days

Persistent CAR-T donor cells contribute to mixed chimerism with cytopenia after CAR-T-bridged allo-HSCT: rescue by CAR-target-knockout DLI in three cases

Authors
Yi Liu; Zelin Wang; Yamei Wu; Xiuwen Xu; Xiaoxia Hu; Jing PanShow moreShow less
Affiliations
1. Senior Department of Hematology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China; 2. Department of Hemato-oncology and Immunotherapy, Beijing Gobroad Hospital, Beijing, China; 3. Department of Medical Laboratory, Beijing Gobroad Boren Hospital, Beijing, China; 4. State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; 5. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, ChinaShow moreShow less
Source PDF DOI Publisher page
80 days

Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy

Authors
Mingxing Wang; Jian Chen; Zhonghua Wu; Zhiying Wang; Zhixian Zhong; Yi ZhongShow moreShow less
Affiliations
1. Shanghai TCM-Integrated Hospital, Shanghai University of TCM, Shanghai, China; 2. Shanghai University of Traditional Chinese Medicine, Shanghai, China; 3. Tongji University, Shanghai, ChinaShow moreShow less
Source PDF DOI Publisher page
112 days

Dynamic regulation of H3K9 modifications in cancer: pathogenesis and targeted therapies

Authors
Yuanyuan Xu; Qihui Wu; Yuxiu Zhang; Jitong Zhao; Xiaodan Fu; Anqi Li; Yimin LiShow moreShow less
Affiliations
1. Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; 2. Department of Gynecology, Xiangya Hospital, Central South University, Changsha, China; 3. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, China; 4. Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China; 5. Department of Pathology, Xiangya Hospital, Central South University, Changsha, ChinaShow moreShow less
Source PDF DOI Publisher page
48 days

AI-driven precision immunotherapy: emerging trends from AACR 2026

Authors
Yani Chen; Ming Chen; Yiqing Xi; Yun Xia; Siyuan Ma; Baoxiang ChenShow moreShow less
Affiliations
1. School of Medicine, Sun Yat-Sen University, Shenzhen, China; 2. Department of Nephrology, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China; 3. Department of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan, China; 4. Department of Head and Neck Surgery, Tongji Medical College, Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China; 5. Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan, China; 6. Electrical and Electronic Engineering, Nanyang Technological University, Singapore, Singapore; 7. Hubei Key Laboratory of Intestinal and Colorectal Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China; 8. Clinical Center of Intestinal and Colorectal Diseases of Hubei Province, Zhongnan Hospital of Wuhan University, Wuhan, China; 9. Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, CanadaShow moreShow less
Source PDF DOI Publisher page
54 days

Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics

Authors
Ruiyi Deng; Boyuan Wang; Mingrui Zou; Kaiyuan Mao; Jiaheng Shang; Jianhui Qiu; Jingcheng Zhou; Hua Xu; Xin Ma; Yizhou Wang; Lin Cai; Kan GongShow moreShow less
Affiliations
1. Department of Urology, Peking University First Hospital, Beijing, China; 2. Institute of Urology, Peking University, Beijing, China; 3. Beijing Key Laboratory of Precision Medicine and Innovative Translation for Urogenital Diseases, Beijing, China; 4. National Urological Cancer Center, Beijing, China; 5. Peking University Health Science Center, Beijing, China; 6. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China; 7. Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan, China; 8. Senior Department of Urology, Chinese PLA General Hospital, Beijing, China; 9. Department of Central Laboratory, Peking University First Hospital, Beijing, ChinaShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.